SCHEMBL17430786

SCHEMBL17430786

C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)C(NO)c3csc(N)n3)[C@H]2SC1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 5/20 0.77
HPGD P15428 1/20 0.77
MAPT P10636 3/20 0.63
ABCC4 O15439 1/20 0.63
CNR1 P21554 1/20 0.63
CTDSP1 Q9GZU7 1/20 0.63
APAF1 O14727 2/20 0.58
LMNA P02545 1/20 0.58
TSHR P16473 1/20 0.58
APEX1 P27695 1/20 0.58
PLCG1 P19174 1/20 0.58
ABCC2 Q92887 1/20 0.58
SIRT5 Q9NXA8 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
PSMD14 O00487 1/20 0.58
MMP2 P08253 1/20 0.58
POLB P06746 1/20 0.52
PKM P14618 1/20 0.52
HTT P42858 1/20 0.52
DUSP3 P51452 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5564580 1.00 TDP1 (0.77) TDP1HPGDMAPTABCC4CNR1
SCHEMBL13287328 0.92 TDP1 (0.76) TDP1HPGDMAPTABCC4CNR1
SCHEMBL9481543 0.90 TDP1 (0.81) TDP1HPGDMAPTABCC4CNR1
SCHEMBL10818943 0.90 TDP1 (0.73) TDP1HPGDMAPTABCC4CNR1
SCHEMBL10818952 0.90 TDP1 (0.73) TDP1HPGDMAPTABCC4CNR1
SCHEMBL13287289 0.90 TDP1 (0.70) TDP1HPGDMAPTABCC4CNR1
SCHEMBL11133665 0.90 TDP1 (0.85) TDP1HPGDMAPTABCC4CNR1
SCHEMBL9480984 0.90 TDP1 (0.85) TDP1HPGDMAPTABCC4CNR1
SCHEMBL9482997 0.82 TDP1 (0.68) TDP1HPGDMAPTABCC4CNR1
SCHEMBL10891854 0.81 TDP1 (0.67) TDP1HPGDMAPTABCC4CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9527878-B2 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-12-27 US disclosed
US-20160009748-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009748-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM SERPINE1, PLAT, SERPINB1 TDP1 2746/4885HPGD 502/4885MAPT 3350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.